Jim Cramer Says He is "Very Upset" With Eli Lilly

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. When a caller inquired about the company during the lightning round, Cramer commented:

“Down here, I begin to think that we are too negative on it, but I am very upset with Lilly in the way they handled this, and I think they should come back on and talk to me because I’m running a drug trial. I would not have done what they did when I was running my drug trial. That’s a private matter, but I can tell you about it. It’s not the way they did it. I think they knew better. They shouldn’t have done it the way they did.”

Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, obesity, cancer, autoimmune disorders, neurological conditions, and other health needs. The company’s portfolio includes treatments that include endocrinology, oncology, immunology, neuroscience, and pain management.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.